JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Patient-preferred sites of restylane injection in periocular and facial soft-tissue augmentation.

PURPOSE: To determine patient-preferred injection sites and frequency for facial volume augmentation with nonanimal stabilized hyaluronic acid (Restylane).

METHODS: : The authors retrospectively reviewed the records of 145 consecutive patients who received 0.4 ml or 1.0 ml subcutaneous facial injections of Restylane. Location, amount, supplemental anesthetic, injection frequency, follow-up time, and use of botulinum toxin type A or other facial aesthetic interventions were reviewed. If recorded, patient satisfaction, revision rate, and any adverse reactions were also noted and analyzed.

RESULTS: Median age at time of initial injection was 54 years; median follow-up was 8 months (mean 10.4 months, range 1-37 months). A total of 309 patient injections were performed (mean, 2.14 injections/patient), with 26% of patients receiving adjunctive anesthesia. Injection site frequencies among the 145 patients were nasolabial folds (72%), melolabial folds (70%), lips (51%), infraorbital rims (24%), perioral rhytids (24%), glabella (23%), malar hollows (10%), chin (8%), and other (8%). Among the 75 patients who received repeat injections, injection intervals were > or =4 months in 56 (76%) and > or =6 months in 28 (38%). Forty-four percent of patients received Botox and Restylane injections during the same office visits. Six complications included edema (2); vasovagal reaction during injection (1); ecchymosis (2); and herpes simplex virus dermatitis (1). Three revisions were performed. One patient was dissatisfied with the procedure.

CONCLUSIONS: Patients elect to undergo Restylane injections to improve the appearance of rhytids and augment volume along infraorbital rims, malar hollows, lips, and depressed scars. Complications are minimal and easily treated.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app